News articles about Cerulean Pharma (NASDAQ:DARE) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerulean Pharma earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.8975717436561 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Cerulean Pharma (NASDAQ DARE) opened at $2.33 on Wednesday. Cerulean Pharma has a twelve month low of $2.24 and a twelve month high of $35.80.
Separately, ValuEngine cut shares of Cerulean Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.
TRADEMARK VIOLATION NOTICE: “Cerulean Pharma (DARE) Receives Media Sentiment Rating of 0.02” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/11/15/cerulean-pharma-dare-receives-media-sentiment-rating-of-0-02.html.
About Cerulean Pharma
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.